Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 11/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468496 | 0.86 | IDO1 (0.37) | METAP2HSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL29484275 | 0.78 | GP6 (0.46) | CYP1A2 | |
| SCHEMBL17900086 | 0.78 | GP6 (0.46) | CYP1A2 | |
| SCHEMBL654803 | 0.77 | METAP2 (0.56) | METAP2CYP3A4ALDH1A1LMNAHSD17B10 | |
| SCHEMBL15860824 | 0.77 | GP6 (0.44) | ESR1 | |
| SCHEMBL5496649 | 0.77 | IDO1 (0.56) | ESR2LMNACDC7 | |
| SCHEMBL3401179 | 0.77 | IDO1 (0.56) | METAP2 | |
| SCHEMBL2652901 | 0.77 | IDO1 (0.56) | METAP2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3398767 | 0.77 | METAP2 (0.56) | METAP2 | |
| SCHEMBL16186300 | 0.77 | IDO1 (0.33) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | PTC THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | claimed |
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12509460-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-114126613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | METAP2 2122/4885HSD17B1 4047/4885HSD17B2 4276/4885 |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | METAP2 3662/4885HSD17B1 2388/4885HSD17B2 2816/4885 |
| US-12509460-B2 | Methods and compositions for modulating splicing | SF3B1, RTCB, RBM17 | METAP2 4277/4885HSD17B1 606/4885HSD17B2 791/4885 |
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | HTT, HYPK, HDAC6 | METAP2 1652/4885HSD17B1 391/4885HSD17B2 284/4885 |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | METAP2 3691/4885HSD17B1 2342/4885HSD17B2 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.